%0 Journal Article
%T Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers.
%A Wang Z
%A Cheng S
%A Yao Y
%A Liu S
%A Liu Z
%A Liu N
%A Jin Y
%A Zhang Y
%A Yin F
%A Han G
%A Zhang J
%A Wang Q
%A Yan D
%A Wang L
%A Lu H
%A Deng T
%A Ji Z
%A Gao H
%A Fang W
%A Zhang H
%A Chen Z
%A Zou J
%A Tang Y
%A Xu C
%A Li J
%A Qu H
%A Bao L
%A Cao B
%A Wang X
%A Xu T
%A Sun Y
%A Shen L
%A Peng Z
%A Li J
%J Cancer Immunol Immunother
%V 73
%N 9
%D 2024 Jul 5
%M 38967817
%F 6.63
%R 10.1007/s00262-024-03764-9
%X <B>BACKGROUND: </B>The long-term survival benefit of immune checkpoint inhibitors (ICIs) in neoadjuvant and adjuvant settings is unclear for colorectal cancers (CRC) and gastric cancers (GC) with deficiency of mismatch repair (dMMR) or microsatellite instability-high (MSI-H).<BR><B>METHODS: </B>This retrospective study enrolled patients with dMMR/MSI-H CRC and GC who received at least one dose of neoadjuvant ICIs (neoadjuvant cohort, NAC) or adjuvant ICIs (adjuvant cohort, AC) at 17 centers in China. Patients with stage IV disease were also eligible if all tumor lesions were radically resectable.<BR><B>RESULTS: </B>In NAC (n = 124), objective response rates were 75.7% and 55.4%, respectively, in CRC and GC, and pathological complete response rates were 73.4% and 47.7%, respectively. The 3-year disease-free survival (DFS) and overall survival (OS) rates were 96% (95%CI 90-100%) and 100% for CRC (median follow-up [mFU] 29.4 months), respectively, and were 84% (72-96%) and 93% (85-100%) for GC (mFU 33.0 months), respectively. In AC (n = 48), the 3-year DFS and OS rates were 94% (84-100%) and 100% for CRC (mFU 35.5 months), respectively, and were 92% (82-100%) and 96% (88-100%) for GC (mFU 40.4 months), respectively. Among the seven patients with distant relapse, four received dual blockade of PD1 and CTLA4 combined with or without chemo- and targeted drugs, with three partial response and one progressive disease.<BR><B>CONCLUSIONS: </B>With a relatively long follow-up, this study demonstrated that neoadjuvant and adjuvant ICIs might be both associated with promising DFS and OS in dMMR/MSI-H CRC and GC, which should be confirmed in further randomized clinical trials.